Literature DB >> 16236959

Influence of heart failure etiology on the prognostic value of peak oxygen consumption and minute ventilation/carbon dioxide production slope.

Ross Arena1, Jonathan Myers, Joshua Abella, Mary Ann Peberdy.   

Abstract

BACKGROUND: Peak oxygen consumption (V(O2)) and minute ventilation (V(E))/carbon dioxide production (V(CO2)) slope have been widely demonstrated to have strong prognostic value in patients with heart failure (HF). In the present study, we investigated the effect of HF etiology on the prognostic applications of peak V(O2) and Ve/V(CO2) slope.
METHODS: Two hundred sixty-eight subjects underwent symptom-limited cardiopulmonary exercise testing (CPX). The population was divided into ischemic (115 men and 22 women) and nonischemic (108 men and 23 women) subgroups. The occurrence of cardiac-related events over the year following CPX was compared between groups using receiver operating characteristic curve (ROC) analysis
RESULTS: Mean age +/- SD was significantly higher (61.0 +/- 10.0 years vs 50.3 +/- 16.2 years) while mean peak V(O2) was significantly lower (15.0 +/- 5.2 mL/kg/min vs 17.5 +/- 6.7 mL/kg/min) in the ischemic HF group (p < 0.05). ROC curve analysis demonstrated that both peak V(O2) and V(E)/V(CO2) slope were significant predictors of cardiac events in both the ischemic group (peak V(O2), 0.74; V(E)/V(CO2) slope, 0.76; p < 0.001) and the nonischemic group (peak V(O2), 0.75; V(E)/V(CO2) slope, 0.86; p < 0.001). Optimal prognostic threshold values for peak V(O2) were 14.1 mL/kg/min and 14.6 mL/kg/min in the ischemic and nonischemic groups, respectively. Optimal prognostic threshold values for the V(E)/V(CO2) slope were 34.2 and 34.5 in the ischemic and nonischemic groups, respectively.
CONCLUSIONS: Baseline and exercise characteristics were different between ischemic and nonischemic patients with HF. However, the prognostic power of the major CPX variables was strikingly similar. Different prognostic classification schemes based on HF etiology may therefore not be necessary when analyzing CPX responses in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236959     DOI: 10.1378/chest.128.4.2812

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Does age attenuate aerobic conditioning response in postmenopausal women? Response.

Authors:  Conrad P Earnest; Steven N Blair; Timothy S Church
Journal:  Eur J Appl Physiol       Date:  2010-12-19       Impact factor: 3.078

Review 2.  The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: an evidence-based review.

Authors:  Ross Arena; Jonathan Myers; Marco Guazzi
Journal:  Heart Fail Rev       Date:  2007-11-07       Impact factor: 4.214

3.  Cardiopulmonary exercise testing is equally prognostic in young, middle-aged and older individuals diagnosed with heart failure.

Authors:  Ross Arena; Jonathan Myers; Joshua Abella; Sherry Pinkstaff; Peter Brubaker; Dalane W Kitzman; Mary Ann Peberdy; Daniel Bensimhon; Paul Chase; Marco Guazzi
Journal:  Int J Cardiol       Date:  2010-06-30       Impact factor: 4.164

4.  VE/VCO2 slope and its prognostic value in patients with chronic heart failure.

Authors:  Yuqin Shen; Xiaoyu Zhang; Wenlin Ma; Haoming Song; Zhu Gong; Qiang Wang; Lin Che; Wenjun Xu; Jinfa Jiang; Jiahong Xu; Wenwen Yan; Lin Zhou; Y I Ni; Guanghe Li; Qiping Zhang; Lemin Wang
Journal:  Exp Ther Med       Date:  2015-02-05       Impact factor: 2.447

5.  An aetiology-based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) trial.

Authors:  Dominika Szalewska; Renata Główczyńska; Ryszard Piotrowicz; Ilona Kowalik; Michael J Pencina; Grzegorz Opolski; Wojciech Zaręba; Maciej Banach; Piotr Orzechowski; Sławomir Pluta; Robert Irzmański; Zbigniew Kalarus; Ewa Piotrowicz
Journal:  ESC Heart Fail       Date:  2021-02-01

Review 6.  Theoretical rationale and practical recommendations for cardiopulmonary exercise testing in patients with chronic heart failure.

Authors:  Lee Ingle
Journal:  Heart Fail Rev       Date:  2007-03-28       Impact factor: 4.654

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.